Who makes Nocardia rubra cell wall skeleton?

Nocardia rubra cell wall skeleton is developed by Wan-Guang Zhang.

What development phase is Nocardia rubra cell wall skeleton in?

Nocardia rubra cell wall skeleton is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Nocardia rubra cell wall skeleton

Wan-Guang Zhang · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Nocardia rubra cell wall skeleton
Also known as	N-CWS, Treatment group
Sponsor	Wan-Guang Zhang
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status (PHASE2)
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC (PHASE1)
Nocardia Cell Wall Skeleton for the Treatment of Diabetic Foot Ulcer Wounds (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nocardia rubra cell wall skeleton CI brief — competitive landscape report
Nocardia rubra cell wall skeleton updates RSS · CI watch RSS
Wan-Guang Zhang portfolio CI